{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:00:09Z","timestamp":1755036009638,"version":"3.38.0"},"reference-count":68,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"DOI":"10.2478\/v10007-010-0040-9","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T03:06:58Z","timestamp":1292641618000},"source":"Crossref","is-referenced-by-count":11,"title":["Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics"],"prefix":"10.2478","volume":"60","author":[{"given":"Una","family":"Glamo\u010dlija","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adlija","family":"Jevri\u0107-\u010cau\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: principles of pathogenesis and therapy","volume":"365","author":"M. Stumvoll","year":"2005","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.20452\/pamw.444","article-title":"Problems in differential diagnosis of diabetes types","volume":"118","author":"M. Ma\u0142ecki","year":"2008","journal-title":"Pol. Arch. Med. Wewn"},{"key":"3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/85405","article-title":"Putting the genes for type 2 diabetes on the map","volume":"7","author":"K. Almind","year":"2001","journal-title":"Nat Med"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030374","article-title":"Combining information from common type 2 diabetes risk polymorphisms improves disease prediction","volume":"3","author":"M. Weedon","year":"2006","journal-title":"PLoS Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ncpendmet0778","article-title":"Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes","volume":"4","author":"R. Murphy","year":"2008","journal-title":"Nat. Clin. Pract. Endocr. Metab"},{"key":"6","first-page":"67","article-title":"Investigating maturity onset diabetes of the young","volume":"30","author":"O. Nyunt","year":"2009","journal-title":"Clin. Biochem. Rev"},{"key":"7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1542\/peds.2007-3543","article-title":"Neonatal and late-onset diabetes mellitus caused by failure of pancreatic development: report of 4 more cases and a review of the literature","volume":"121","author":"C. Rongrong","year":"2008","journal-title":"Pediatrics"},{"key":"8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1210\/er.2007-0029","article-title":"Neonatal diabetes mellitus","volume":"29","author":"L. Aguilar-Bryan","year":"2008","journal-title":"Endocr. Rev"},{"key":"9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-2-12","article-title":"Neonatal diabetes mellitus: a disease linked to multiple mechanisms","volume":"2","author":"M. Polak","year":"2007","journal-title":"Orphanet J. Rare Dis"},{"key":"10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics - drug disposition, drug targets and side effects","volume":"6","author":"W. Evans","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"R. Weinshilboum","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics","volume":"286","author":"W. Evans","year":"1999","journal-title":"Science"},{"key":"13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMe0805136","article-title":"Pharmacogenomics and drug toxicity","volume":"8","author":"Y. Nakamura","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"R. Wilke","year":"2007","journal-title":"Nat. Rev. Drug. Discov"},{"key":"15","first-page":"131","article-title":"Frequency of C3435 MDR1 and A6896G CYP3A5 single nucleotide polymorphism in an Iranian population and comparison with other ethnic groups","volume":"20","author":"N. Azarpira","year":"2006","journal-title":"Mod. J. Ist. Rep. Iran"},{"key":"16","unstructured":"J. L. Evans and R. J. Rushakoff, Oral Pharmacological Agents for Type 2 Diabetes: Oral Agents, Incretions and other \u00bbNon-Insulin\u00ab Pharmacologic Interventions for Diabetes, <i>Endo Text. Org. - The Endocrine Source, Diabetes Manager<\/i> (Eds. I. D. Goldfine and R. J. Rushakoff) last author version May 2010; <a target=\"_blank\" href='http:\/\/diabetesmanager.pbworks.com\/w\/page\/17680289\/Oral-Pharmacological-Agents-for-Type-2-Diabetes'>http:\/\/diabetesmanager.pbworks.com\/w\/page\/17680289\/Oral-Pharmacological-Agents-for-Type-2-Diabetes<\/a>"},{"key":"17","first-page":"89","volume-title":"Farmakoterapijski priru\u010dnik","author":"B. Vrhovac","year":"2003"},{"key":"18","first-page":"106","volume-title":"Registar lijekova s osnovama farmakoterapije 11","author":"N. Mulabegovi\u0107","year":"2009"},{"issue":"1","key":"19","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2009.09077","article-title":"Type 2 diabetes: where we are today: An overview of disease burden, current treatments, and treatment strategies","volume":"49","author":"R. Campbell","year":"2009","journal-title":"J. Am. Pharm. Assoc"},{"key":"20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1172\/JCI32133","article-title":"Pharmacogenetics of metformin response: a step in the path toward personalized medicine","volume":"117","author":"M. Reitman","year":"2007","journal-title":"J. Clin. Invest"},{"key":"21","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.2337\/db08-0343","article-title":"Learning from molecular genetics. Novel insights arising from the definition of genes for monogenic and type 2 diabetes","volume":"57","author":"M. McCarthy","year":"2008","journal-title":"Diabetes"},{"key":"22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1172\/JCI200422506","article-title":"Unlocking the secrets of the pancreatic \u03b2 cell: man and mouse provide the key","volume":"114","author":"A. Hattersley","year":"2004","journal-title":"J. Clin. Invest"},{"key":"23","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1210\/en.2006-0152","article-title":"Minireview: Pharmacogenetics and beyond: The interaction of therapeutic response, \u03b2-cell physiology, and genetics in diabetes","volume":"147","author":"A. Hattersley","year":"2006","journal-title":"Endocrinology"},{"key":"24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.4238\/vol8-2gmr597","article-title":"Screening of mutations in the GCK gene in Jordanian maturity-onset diabetes of the young type 2 (MODY2) patients","volume":"8","author":"R. Khalil","year":"2009","journal-title":"Genet. Mol. Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1371\/journal.pone.0001870","article-title":"Glucokinase gene mutations: Structural and genotype-phenotype analyses in MODY children from south Italy","volume":"3","author":"N. Tinto","year":"2008","journal-title":"PLoS One"},{"key":"26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJM199303113281005","article-title":"Familial hyperglycemia due to mutations in glucokinase - definition of a subtype of diabetes mellitus","volume":"328","author":"P. Froguel","year":"1993","journal-title":"N. Engl. J. Med"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.2007.S101","article-title":"\u03b2-Cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1\u03b1 and glucokinase mutations","volume":"50","author":"E. Pearson","year":"2001","journal-title":"Diabetes"},{"key":"28","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/diacare.28.7.1751","article-title":"\u03b2-Cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1\u03b1 mutation carriers","volume":"28","author":"A. Stride","year":"2005","journal-title":"Diabetes Care"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.2007.S94","article-title":"\u03b2-Cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors","volume":"50","author":"T. Frayling","year":"2001","journal-title":"Diabetes"},{"key":"30","doi-asserted-by":"publisher","first-page":"24457","DOI":"10.1074\/jbc.273.38.24457","article-title":"Defective pancreatic \u03b2-cell glycolytic signaling in hepatocyte nuclear factor-1\u03b1-deficient mice","volume":"273","author":"I. Dukes","year":"1998","journal-title":"J. Biol. Chem"},{"key":"31","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1093\/emboj\/19.16.4257","article-title":"Molecular targets of a human HNF1\u03b1 mutation responsible for pancreatic \u03b2-cell dysfunction","volume":"19","author":"H. Wang","year":"2000","journal-title":"EMBO J"},{"key":"32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1046\/j.1464-5491.2000.00305.x","article-title":"Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor 1\u03b1 gene mutations: evidence for pharmacogenetics in diabetes","volume":"17","author":"E. Pearson","year":"2000","journal-title":"Diabetic Med"},{"key":"33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"E. Pearson","year":"2003","journal-title":"Lancet"},{"key":"34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2337\/diabetes.51.2007.S343","article-title":"Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1\u03b1-deficient mice. A mechanism for hypersensitivity to sulfonylurea therapy in patients with Maturity-Onset Diabetes of the Young, Type 3 (MODY3)","volume":"51","author":"P. Boileau","year":"2002","journal-title":"Diabetes"},{"key":"35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2337\/diacare.22.5.867","article-title":"A case of hepatocyte nuclear factor-1\u03b1 diabetes\/MODY 3 masquerading as type 1 diabetes in a Mexican-American adolescent and responsive to a low dose of sulphonylurea (letter)","volume":"22","author":"E. Hathout","year":"1999","journal-title":"Diabetes Care"},{"key":"36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2337\/diacare.26.2.333","article-title":"P. Bingley and A. T. Hattersley, Identifying hepatic nuclear factor 1\u03b1 mutations in children and young adults with a clinical diagnosis of type 1 diabetes","volume":"26","author":"A. Lambert","year":"2003","journal-title":"Diabetes Care"},{"key":"37","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.2337\/diacare.26.11.3191-a","article-title":"No deterioration in glycemic control in HNF-1\u03b1 maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas","volume":"26","author":"M. Shepherd","year":"2003","journal-title":"Diabetes Care"},{"key":"38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/hmg\/8.11.2001","article-title":"A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1\u03b2","volume":"8","author":"T. Lindner","year":"1999","journal-title":"Hum. Mol. Genet"},{"key":"39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/diacare.27.5.1102","article-title":"Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1\u03b1 and -1\u03b2 mutations","volume":"27","author":"E. Pearson","year":"2004","journal-title":"Diabetes Care"},{"key":"40","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1093\/hmg\/ddg355","article-title":"Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas","volume":"12","author":"M. Maestro","year":"2003","journal-title":"Hum. Mol. Genet"},{"key":"41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2337\/db06-1275","article-title":"An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes","volume":"56","author":"R. Masia","year":"2007","journal-title":"Diabetes"},{"key":"42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMe068142","article-title":"ATP-sensitive potassium channels - neonatal diabetes mellitus and beyond","volume":"355","author":"M. Sperling","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1085\/jgp.200308878","article-title":"Gating mechanism of KATP channels: function fits form","volume":"5","author":"D. Enkvetchakul","year":"2003","journal-title":"J. Gen. Physiol"},{"key":"44","doi-asserted-by":"publisher","first-page":"17539","DOI":"10.1073\/pnas.0404756101","article-title":"Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features","volume":"101","author":"P. Proks","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1056\/NEJMoa061759","article-title":"Neonatal diabetes international collaborative group, Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations","volume":"355","author":"E. Pearson","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"46","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.2337\/diabetes.54.9.2645","article-title":"ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy","volume":"54","author":"J. Koster","year":"2005","journal-title":"Diabetes"},{"key":"47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1056\/NEJMoa055068","article-title":"Activating mutations in the ABCC8 gene in neonatal diabetes mellitus","volume":"355","author":"A. Babenko","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2337\/dc07-1785","article-title":"The Neonatal diabetes international collaborative group, Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations","volume":"31","author":"M. Rafiq","year":"2008","journal-title":"Diabetes Care"},{"key":"49","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1210\/jc.2004-1241","article-title":"Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2","volume":"89","author":"A. Zung","year":"2004","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050206","article-title":"Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic \u03b2-cells","volume":"5","author":"M. Remedi","year":"2008","journal-title":"PLoS Med"},{"key":"51","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2005-2323","article-title":"The E23K variant of <i>KCNJ11<\/i> encoding the pancreatic \u03b2-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes","volume":"91","author":"G. Sesti","year":"2006","journal-title":"J. Clin. Endocr. Metab"},{"key":"52","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","article-title":"Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance","volume":"44","author":"J. Kirchheiner","year":"2005","journal-title":"Clin. Pharmacokin"},{"key":"53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2125.2005.02379.x","article-title":"Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents","volume":"60","author":"A. Holstein","year":"2005","journal-title":"Br. J. Clin. Pharmacol"},{"key":"54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1067\/mcp.2002.122476","article-title":"Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers","volume":"71","author":"J. Kirchheiner","year":"2002","journal-title":"Clin. Pharmacol. Ther"},{"key":"55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1067\/mcp.2002.122476","article-title":"Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers","volume":"12","author":"J. Kirchheiner","year":"2002","journal-title":"Pharmacogenetics"},{"key":"56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/00003088-200443040-00005","article-title":"Influence of CYP2C9 and CYP2D6 polymorphisms on pharmacokinetics of nateglinide in genotyped healthy volunteers","volume":"43","author":"J. Kirchheiner","year":"2004","journal-title":"J. Clin. Pharmacokin"},{"key":"57","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/aps.2010.47","article-title":"IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population","volume":"31","author":"Q. Huang","year":"2010","journal-title":"Acta Pharmacol. Sin"},{"key":"58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03256250","article-title":"Pharmacogenetics of glucose-lowering drug treatment: a systematic review","volume":"11","author":"O. Bozkurt","year":"2007","journal-title":"Mol. Diagn. Ther"},{"key":"59","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Y. Shu","year":"2007","journal-title":"J. Clin. Invest"},{"key":"60","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/jpet.102.034140","article-title":"Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin","volume":"302","author":"D. Wang","year":"2002","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2133\/dmpk.20.379","article-title":"Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1, Drug Metab","volume":"20","author":"N. Kimura","year":"2005","journal-title":"Pharmacokin"},{"key":"62","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.2337\/db07-0440","article-title":"Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study","volume":"56","author":"E. Pearson","year":"2007","journal-title":"Diabetes"},{"key":"63","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.2337\/diabetes.54.11.3319","article-title":"Sequence variation in <i>PPARG<\/i> may underlie differential response to troglitazone","volume":"54","author":"J. Wolford","year":"2005","journal-title":"Diabetes"},{"key":"64","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2337\/diacare.27.6.1365","article-title":"Troglitazone in prevention of diabetes (TRIPOD) study, Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala PPAR-\u03b3-2 gene variant: results from the troglitazone in prevention of diabetes (TRIPOD) study","volume":"27","author":"S. Snitker","year":"2004","journal-title":"Diabetes Care"},{"key":"65","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2337\/diacare.26.3.825","article-title":"Analysis of the relationship between the Pro12Ala variant in the PPAR-\u03b32 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes","volume":"26","author":"M. Bl\u00fcher","year":"2003","journal-title":"Diabetes Care"},{"key":"66","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/0091270009355159","article-title":"Effects of the peroxisome proliferator activated receptor-\u03b3 coactivator-1\u03b1 (PGC-1\u03b1) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus","volume":"50","author":"K. Zhang","year":"2010","journal-title":"J. Clin. Pharmacol"},{"key":"67","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.2337\/diabetes.54.6.1854","article-title":"Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes","volume":"54","author":"H. Pan","year":"2005","journal-title":"Diabetes"},{"key":"68","doi-asserted-by":"publisher","first-page":"47402","DOI":"10.1074\/jbc.M404027200","article-title":"Targeted deletion of hepatic CTP: phosphocholine cytidyltransferase a in mice decreases plasma high density and very low density lipoproteins","volume":"279","author":"R. Jacobs","year":"2004","journal-title":"J. Biol. Chem"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/view\/j\/acph.2010.60.issue-4\/v10007-010-0040-9\/v10007-010-0040-9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T23:12:01Z","timestamp":1740784321000},"score":1,"resource":{"primary":{"URL":"https:\/\/content.sciendo.com\/doi\/10.2478\/v10007-010-0040-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,1]]},"references-count":68,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.2478\/v10007-010-0040-9","relation":{},"ISSN":["1846-9558","1330-0075"],"issn-type":[{"type":"electronic","value":"1846-9558"},{"type":"print","value":"1330-0075"}],"subject":[],"published":{"date-parts":[[2010,1,1]]}}}